mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2015-4-98-105mrj-660Research ArticleОБЗОРЫREVIEWSHLA-B27-ассоциированный увеит: от патогенеза к терапииHLA-B27-associated uveitis: From pathogenesis to therapyДеминаА. Б.DeminaA. B.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

deminaab@yandex.ruДубининаТ. В.DubininaT. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ЭрдесШ. Ф.ErdesSh. F.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ Научно-исследовательский институт ревматологии им В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2015140120169498105Copyright © Демина А.Б., Дубинина Т.В., Эрдес Ш.Ф., 20162016Демина А.Б., Дубинина Т.В., Эрдес Ш.Ф.Demina A.B., Dubinina T.V., Erdes S.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/660

Увеит – воспаление сосудистой оболочки глаза, которое возникает, как правило, у лиц молодого возраста и может сопровождаться развитием серьезных осложнений, приводящих к инвалидности. В обзоре проанализированы данные отечественных и зарубежных исследований, касающиеся патогенеза HLA-B27-ассоциированного увеита, возникающего при различных заболеваниях из группы серонегативных спондилоартритов (СпА), а также обсуждаются современные терапевтические подходы при данном заболевании.

С конца ХХ в. отмечается бурный прогресс в изучении патогенеза HLA-B27-ассоциированного увеита и выявлении генетических факторов, предрасполагающих к возникновению этой патологии. Продолжается изучение HLA-B27-антигена и его аллелей. Среди медиаторов воспаления наиболее исследованным является фактор некроза опухоли α (ФНОα), повышение уровня которого при ревматических заболеваниях в крови, синовиальной жидкости и жидких средах глаза доказано во многих работах как зарубежных, так и отечественных ученых. В связи с ключевой ролью данного цитокина в развитии воспаления в последние десятилетия созданы и успешно применяются препараты, подавляющие активность ФНОα, что приводит к частичной, а иногда и стойкой ремиссии.

Uveitis is the inflammation of the uvea, which generally occurs in young people and may be accompanied by serious complications leading to disability. The review analyzes the data of Russian and foreign investigations on the pathogenesis of HLA-B27-associated uveitis occurring in different diseases from a group of seronegative spondyloarthritides (SpA) and also discusses current therapeutic approaches in this disease.

Since the late 20th century, there has been rapid progress in studying the pathogenesis of HLA-B27-associated uveitis and in identifying the genetic factors predisposing to this pathology. Investigations of HLA-B27 antigen and its alleles are being continued. Tumor necrosis factor-α (TNF-α), the higher levels of which in blood, synovial fluid, and ocular fluid in rheumatic diseases has been proven in many works of both foreign and Russian scientists, is most studied among the inflammatory mediators. Due to the key role of this cytokine in the development of inflammation, drugs inhibiting TNF-α activity have been designed and successfully used in the past decade, which results in partial and occasionally stable remission.

HLA-B27-ассоциированный увеитспондилоартритингибиторы фактора некроза опухоли αHLA-27-associated uveitisspondyloarthritistumor necrosis factor-α inhibitorsReferencesGran OT, Skomvoll JF. The outcome of ankilosing spondylitis: a study of 100 patients. Br J Rheumatol. 1997 Jul;36(7):766-71.Gran OT, Skomvoll JF. The outcome of ankilosing spondylitis: a study of 100 patients. Br J Rheumatol. 1997 Jul;36(7):766-71.Bodaghi B, Cassoux N, Wechsler B, et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore). 2001 Jul;80(4):263-70.Bodaghi B, Cassoux N, Wechsler B, et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore). 2001 Jul;80(4):263-70.Зайцева НС, Кацнельсон ЛА. Увеиты. Москва: Медицина; 1984. 318 с. [Zaitseva NS, Katsnel'son LA. Uveity [Uveitis]. Moscow: Meditsina; 1984. 318 p.]Зайцева НС, Кацнельсон ЛА. Увеиты. Москва: Медицина; 1984. 318 с. [Zaitseva NS, Katsnel'son LA. Uveity [Uveitis]. Moscow: Meditsina; 1984. 318 p.]Edmunds L, Elswood J, Calin A. New light on uveitis in ankylosing spondylitis. J Rheumatol. 1991 Jan;18(1):50-2.Edmunds L, Elswood J, Calin A. New light on uveitis in ankylosing spondylitis. J Rheumatol. 1991 Jan;18(1):50-2.Banares A, Hernandez-Garcia C, Fernandez-Gutierrez B, Jover JA. Eye involvement in the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4):771-84, ix.Banares A, Hernandez-Garcia C, Fernandez-Gutierrez B, Jover JA. Eye involvement in the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4):771-84, ix.Fernandez-Melon J, Munoz-Fernandez S, Hidalgo V, et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. J Rheumatol. 2004 Mar;31(3):524-7.Fernandez-Melon J, Munoz-Fernandez S, Hidalgo V, et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. J Rheumatol. 2004 Mar;31(3):524-7.Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A27. Lancet. 1973 Apr 28;1(7809):904-7.Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A27. Lancet. 1973 Apr 28;1(7809):904-7.Brewerton DA, Caffrey M, Nicholls A, et al. Acute anterior uveitis and HL-A27. Lancet. 1973 Nov 3;302(7836):994-6.Brewerton DA, Caffrey M, Nicholls A, et al. Acute anterior uveitis and HL-A27. Lancet. 1973 Nov 3;302(7836):994-6.Ehlers N, Kissmeyer-Nielsen F, Kjerbye KE, Lamm LU. Letter: HL-A27 in acute and chronic uveitis. Lancet. 1974 Jan 19;1(7847):99.Ehlers N, Kissmeyer-Nielsen F, Kjerbye KE, Lamm LU. Letter: HL-A27 in acute and chronic uveitis. Lancet. 1974 Jan 19;1(7847):99.Woodrow JC, Mapstone R, Anderson J, Usher N. HL-A27 and anterior uveitis. Tissue Antigens. 1975 Sep;6(3):116-20.Woodrow JC, Mapstone R, Anderson J, Usher N. HL-A27 and anterior uveitis. Tissue Antigens. 1975 Sep;6(3):116-20.Rahi AH. HLA and eye disease. Br J Ophthalmol. 1979 May;63(5):283-92.Rahi AH. HLA and eye disease. Br J Ophthalmol. 1979 May;63(5):283-92.Ревматология: национальное руководство. Насонов ЕЛ, редактор. Москва: Гэотар-Медиа; 2008. С. 333-4. [Revmatologiya: natsional'noe rukovodstvo [Rheumatology: National Guide]. Nasonov EL, editor. Moscow: Geotar-Media; 2008. P. 333-4.]Ревматология: национальное руководство. Насонов ЕЛ, редактор. Москва: Гэотар-Медиа; 2008. С. 333-4. [Revmatologiya: natsional'noe rukovodstvo [Rheumatology: National Guide]. Nasonov EL, editor. Moscow: Geotar-Media; 2008. P. 333-4.]Breban M, Hacquard-Bouder C, Falgarone G. Animal models of HLA-B27-associated diseases. Curr Mol Med. 2004 Feb;4(1):31-40.Breban M, Hacquard-Bouder C, Falgarone G. Animal models of HLA-B27-associated diseases. Curr Mol Med. 2004 Feb;4(1):31-40.Breban M, Hammer RE, Richardson JA, Taurog JD. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med. 1993 Nov 1;178(5):1607-16.Breban M, Hammer RE, Richardson JA, Taurog JD. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med. 1993 Nov 1;178(5):1607-16.Breban M, Fernandez-Sueiro JL, Richardson JA, et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol. 1996 Jan 15;156(2):794-803.Breban M, Fernandez-Sueiro JL, Richardson JA, et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol. 1996 Jan 15;156(2):794-803.Taurog JD, Maika S, Satumtira N, et al. Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev. 1999 Jun;169:209-23.Taurog JD, Maika S, Satumtira N, et al. Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev. 1999 Jun;169:209-23.Hacquard-Bouder C, Falgarone G, Bosquet A, et al. Defective Costimulatory Function Is a Striking Feature of AntigenPresenting Cells in an HLA-B27-Transgenic Rat Model of Spondylarthropathy. Arthritis Rheum. 2004 May;50(5):1624-35.Hacquard-Bouder C, Falgarone G, Bosquet A, et al. Defective Costimulatory Function Is a Striking Feature of AntigenPresenting Cells in an HLA-B27-Transgenic Rat Model of Spondylarthropathy. Arthritis Rheum. 2004 May;50(5):1624-35.Fabian H, Huser H, Loll B, et al. HLA-B27 Heavy Chains Distinguished by a Micropolymorphism Exhibit Differential Flexibility. Arthritis Rheum. 2010 Apr;62(4):978-87. doi: 10.1002/art.27316.Fabian H, Huser H, Loll B, et al. HLA-B27 Heavy Chains Distinguished by a Micropolymorphism Exhibit Differential Flexibility. Arthritis Rheum. 2010 Apr;62(4):978-87. doi: 10.1002/art.27316.Zambrano-Zaragoza JF, Agraz-Cibrian JM, Gonzalez-Reyes C, et al. Ankylosing Spondylitis: From Cells to Genes. Int J Inflam. 2013;2013:501653. doi: 10.1155/2013/501653. Epub 2013 Jul 21.Zambrano-Zaragoza JF, Agraz-Cibrian JM, Gonzalez-Reyes C, et al. Ankylosing Spondylitis: From Cells to Genes. Int J Inflam. 2013;2013:501653. doi: 10.1155/2013/501653. Epub 2013 Jul 21.Nasution AR, Mardjuadi A, Kunmartini S. HLA-B27 subtypes positively and negatively associated with spondiloarthropathy. J Rheumatol. 1997 Jun;24(6):1111-4.Nasution AR, Mardjuadi A, Kunmartini S. HLA-B27 subtypes positively and negatively associated with spondiloarthropathy. J Rheumatol. 1997 Jun;24(6):1111-4.Lin J, Lu H, Feng C. Ankylosing spondylitis and heterogeneity of HLA-B27 in Chinese. Chin Med J (Engl). 1996 Apr;109(4):313-6.Lin J, Lu H, Feng C. Ankylosing spondylitis and heterogeneity of HLA-B27 in Chinese. Chin Med J (Engl). 1996 Apr;109(4):313-6.Kanga U, Mehra NK, Larrea CL, et al. Seronegative spondyloarthropathies and HLA-B27 subtyes: a study in Asian Indians. Clin Rheumatol. 1996 Jan;15 Suppl 1:13-8.Kanga U, Mehra NK, Larrea CL, et al. Seronegative spondyloarthropathies and HLA-B27 subtyes: a study in Asian Indians. Clin Rheumatol. 1996 Jan;15 Suppl 1:13-8.Nasution AR, Mardjuadi A, Suryadhana NG, et al. Higher relative risk of spondyloarthropathies among B27 positive Indonesian Chinese than native Indonesians. J Rheumatol. 1993 Jun;20(6):988-90.Nasution AR, Mardjuadi A, Suryadhana NG, et al. Higher relative risk of spondyloarthropathies among B27 positive Indonesian Chinese than native Indonesians. J Rheumatol. 1993 Jun;20(6):988-90.Van Gaalen FA. Does HLA-B*2706 protect against ankylosing spondylitis? A metaanalysis. Int J Rheum Dis. 2012 Feb;15(1): 8-12. doi: 10.1111/j.1756-185X.2011.01676.x. Epub 2011 Oct 18.Van Gaalen FA. Does HLA-B*2706 protect against ankylosing spondylitis? A metaanalysis. Int J Rheum Dis. 2012 Feb;15(1): 8-12. doi: 10.1111/j.1756-185X.2011.01676.x. Epub 2011 Oct 18.Qi J, Li Q, Lin Z, et al. Higher risk of uveitis and dactylitis and older age of onset among ankylosing spondylitis patients with HLA-B*2705 than patients with HLA-B*2704 in the Chinese population. Tissue Antigens. 2013 Dec;82(6):380-6. doi: 10.1111/tan.12254.Qi J, Li Q, Lin Z, et al. Higher risk of uveitis and dactylitis and older age of onset among ankylosing spondylitis patients with HLA-B*2705 than patients with HLA-B*2704 in the Chinese population. Tissue Antigens. 2013 Dec;82(6):380-6. doi: 10.1111/tan.12254.Chavan H, Samant R, Deshpande A, Mankeshwar R. Correlation of HLA B27 subtypes with clinical features of ankylosing spondylitis. Int J Rheum Dis. 2011 Oct;14(4):369-74. doi: 10.1111/j.1756-185X.2011.01635.x. Epub 2011 Sep 19.Chavan H, Samant R, Deshpande A, Mankeshwar R. Correlation of HLA B27 subtypes with clinical features of ankylosing spondylitis. Int J Rheum Dis. 2011 Oct;14(4):369-74. doi: 10.1111/j.1756-185X.2011.01635.x. Epub 2011 Sep 19.Дроздова ЕА. Увеит при ревматических заболеваниях: особенности клиники, диагностика, иммунопатогенез и лечение (диссертация на соискание доктора медицинских наук). Уральская государственная Академия Дополнительного Образования; 2006. [Drozdova EA. Uveitis in rheumatic diseases: clinical features, diagnosis, immunopathogenesis and treatment (diss. doct. med. sci.). Ural'skaya gosudarstvennaya Akademiya Dopolnitel'nogo Obrazovaniya; 2006.]Дроздова ЕА. Увеит при ревматических заболеваниях: особенности клиники, диагностика, иммунопатогенез и лечение (диссертация на соискание доктора медицинских наук). Уральская государственная Академия Дополнительного Образования; 2006. [Drozdova EA. Uveitis in rheumatic diseases: clinical features, diagnosis, immunopathogenesis and treatment (diss. doct. med. sci.). Ural'skaya gosudarstvennaya Akademiya Dopolnitel'nogo Obrazovaniya; 2006.]Сапроненков ПМ, Тюрин ВП. Современные направления диагностики и лечения анкилозирующего спрондилоартрита. Военно-медицинский журнал. 1990;(7):52-5. [Sapronenkov PM, Tyurin VP. Modern trends in diagnosis and treatment of ankylosing spondyloarthritis. Voenno-meditsinskii zhurnal. 1990;(7):52-5. (In Russ.)].Сапроненков ПМ, Тюрин ВП. Современные направления диагностики и лечения анкилозирующего спрондилоартрита. Военно-медицинский журнал. 1990;(7):52-5. [Sapronenkov PM, Tyurin VP. Modern trends in diagnosis and treatment of ankylosing spondyloarthritis. Voenno-meditsinskii zhurnal. 1990;(7):52-5. (In Russ.)].Ковалёв ЮН. Прогнозирование течения болезни Рейтера с помощью антигенов гистосовместимости. Ревматология. 1989;(12):33-6. [Kovalev YuN. Prognosis of Reiter's disease by using antigens of histocompatibility. Revmatologiya. 1989;(12):33-6. (In Russ.)].Ковалёв ЮН. Прогнозирование течения болезни Рейтера с помощью антигенов гистосовместимости. Ревматология. 1989;(12):33-6. [Kovalev YuN. Prognosis of Reiter's disease by using antigens of histocompatibility. Revmatologiya. 1989;(12):33-6. (In Russ.)].Monowarul Islam SM, Numaga J, Fujino Y, et al. HLA-DR8 and acute anterior uveitis in Ankylosing spondilitis. Arthritis Rheum. 1995 Apr;38(4):547-50.Monowarul Islam SM, Numaga J, Fujino Y, et al. HLA-DR8 and acute anterior uveitis in Ankylosing spondilitis. Arthritis Rheum. 1995 Apr;38(4):547-50.Pimentel-Santos FM, Matos M, Ligeiro D, et al. HLA alleles and HLA-B27 haplotypes associated with susceptibility and severity of ankylosing spondylitis in a Portuguese population. Tissue Antigens. 2013 Dec;82(6):374-9. doi: 10.1111/tan.12238.Pimentel-Santos FM, Matos M, Ligeiro D, et al. HLA alleles and HLA-B27 haplotypes associated with susceptibility and severity of ankylosing spondylitis in a Portuguese population. Tissue Antigens. 2013 Dec;82(6):374-9. doi: 10.1111/tan.12238.Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечение ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 552 с. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenie revmatoidnogo artrita [Genetically engineered biological drugs in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 552 p.]Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечение ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 552 с. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenie revmatoidnogo artrita [Genetically engineered biological drugs in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 552 p.]Ярилин AA. Система цитокинов и принципы еe функционирования в норме и при патологии. Иммунология. 1997;(5):7-13. [Yarilin AA. The system of cytokines and principles of its functioning in norm and pathology. Immunologiya. 1997;(5):7-13. (In Russ.)].Ярилин AA. Система цитокинов и принципы еe функционирования в норме и при патологии. Иммунология. 1997;(5):7-13. [Yarilin AA. The system of cytokines and principles of its functioning in norm and pathology. Immunologiya. 1997;(5):7-13. (In Russ.)].Насонов ЕЛ, Баранов АА, Шилкина НП. Васкулиты и васкулопатии. Ярославль: Верхняя Волга; 1999. 49 c. [Nasonov EL, Baranov AA, Shilkina NP. Vaskulity i vaskulopatii [Vasculitis and vasculopathy]. Yaroslavl': Verkhnyaya Volga; 1999. 49 p.]Насонов ЕЛ, Баранов АА, Шилкина НП. Васкулиты и васкулопатии. Ярославль: Верхняя Волга; 1999. 49 c. [Nasonov EL, Baranov AA, Shilkina NP. Vaskulity i vaskulopatii [Vasculitis and vasculopathy]. Yaroslavl': Verkhnyaya Volga; 1999. 49 p.]Насонова ВА, Насонов ЕЛ, редакторы. Рациональная фармакотерапия ревматических заболеваний. Москва: Литтерра; 2003. 800 с. [Nasonova VA, Nasonov EL, editors. Ratsional'naya farmakoterapiya revmaticheskikh zabolevanii [Rational pharmacotherapy of rheumatic diseases]. Moscow: Litterra; 2003. 800 p.]Насонова ВА, Насонов ЕЛ, редакторы. Рациональная фармакотерапия ревматических заболеваний. Москва: Литтерра; 2003. 800 с. [Nasonova VA, Nasonov EL, editors. Ratsional'naya farmakoterapiya revmaticheskikh zabolevanii [Rational pharmacotherapy of rheumatic diseases]. Moscow: Litterra; 2003. 800 p.]Preffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003 JunAug;14(3-4):185-91.Preffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003 JunAug;14(3-4):185-91.Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4 Suppl 3:S233-42. Epub 2002 May 9.Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4 Suppl 3:S233-42. Epub 2002 May 9.Santos Lacomba M, Marcos MartТn C, Gallardo Galera JM, et al. Aqueous humor and serum interleukin-6 in patients with uveitis. Arch Soc Esp Oftalmol. 2001 Jun;76(6):345-50.Santos Lacomba M, Marcos MartТn C, Gallardo Galera JM, et al. Aqueous humor and serum interleukin-6 in patients with uveitis. Arch Soc Esp Oftalmol. 2001 Jun;76(6):345-50.Tanaka T, Kuwahara Y, Shima Y, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum. 2009 Dec 15;61(12):1762-4. doi: 10.1002/art.24899.Tanaka T, Kuwahara Y, Shima Y, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum. 2009 Dec 15;61(12):1762-4. doi: 10.1002/art.24899.Brulhart L, Nissen MJ, Chevallier P, et al. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine. 2010 Dec;77(6):625-6. doi: 10.1016/j.jbspin.2010.08.004. Epub 2010 Sep 20.Brulhart L, Nissen MJ, Chevallier P, et al. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine. 2010 Dec;77(6):625-6. doi: 10.1016/j.jbspin.2010.08.004. Epub 2010 Sep 20.Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol. 2011 Jul;38(7):1527. doi: 10.3899/jrheum.110265.Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol. 2011 Jul;38(7):1527. doi: 10.3899/jrheum.110265.ZouW, Wu Z, Xiang X, et al. The expression and significance of T helper cell subsets and regulatory T cells CD4 (+)CD 25 (+) in peripheral blood of patients with human leukocyte antigen B27-positive acute anterior uveitis. Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):665-72. doi: 10.1007/s00417-014-2567-9. Epub 2014 Jan 31.ZouW, Wu Z, Xiang X, et al. The expression and significance of T helper cell subsets and regulatory T cells CD4 (+)CD 25 (+) in peripheral blood of patients with human leukocyte antigen B27-positive acute anterior uveitis. Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):665-72. doi: 10.1007/s00417-014-2567-9. Epub 2014 Jan 31.Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76. doi: 10.1038/nrd3794.Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76. doi: 10.1038/nrd3794.Yeremenko N, Baeten D. IL-17 in spondyloarthritis: is the T-party over? Arthritis Res Ther. 2011 Jun 24;13(3):115. doi: 10.1186/ar3351.Yeremenko N, Baeten D. IL-17 in spondyloarthritis: is the T-party over? Arthritis Res Ther. 2011 Jun 24;13(3):115. doi: 10.1186/ar3351.Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821-52.Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821-52.Jiang G, Ke Y, Sun D, et al. Reactivation of Uveitogenic T Cells by Retinal Astrocytes Derived from Experimental Autoimmune Uveitis-Prone B10RIII Mice. Invest Ophthalmol Vis Sci. 2008 Jan;49(1):282-9. doi: 10.1167/iovs.07-0371.Jiang G, Ke Y, Sun D, et al. Reactivation of Uveitogenic T Cells by Retinal Astrocytes Derived from Experimental Autoimmune Uveitis-Prone B10RIII Mice. Invest Ophthalmol Vis Sci. 2008 Jan;49(1):282-9. doi: 10.1167/iovs.07-0371.Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011 Feb 15;186(4):2672-80. doi: 10.4049/jimmunol.1002653. Epub 2011 Jan 19.Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011 Feb 15;186(4):2672-80. doi: 10.4049/jimmunol.1002653. Epub 2011 Jan 19.Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol. 2014 Jan;57(1):28-37. doi: 10.1016/j.molimm.2013. 07.016. Epub 2013 Aug 19.Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol. 2014 Jan;57(1):28-37. doi: 10.1016/j.molimm.2013. 07.016. Epub 2013 Aug 19.Zierhut M1, Feltkamp B, Forrester J, et al. Immunology of the eye and the joint. Immunol Today. 1994 Jun;15(6):249-51.Zierhut M1, Feltkamp B, Forrester J, et al. Immunology of the eye and the joint. Immunol Today. 1994 Jun;15(6):249-51.Butler TL, McMenamin PG. Resident and infiltrating immune cells in the uveal tract in the early and late stages of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2195-210.Butler TL, McMenamin PG. Resident and infiltrating immune cells in the uveal tract in the early and late stages of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2195-210.Prendergast RA, Iliff CE, Coskuncan NM, et al. T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 1998 Apr;39(5):754-62.Prendergast RA, Iliff CE, Coskuncan NM, et al. T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 1998 Apr;39(5):754-62.Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alfa in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3884-9.Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alfa in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3884-9.Martin T, Smith J, Rosenbaum J. Anterior uveitis: current concepts of pathogenesis and nteractions with the spondyloarthropathies. Curr Opin Rheumatol. 2002 Jul;14(4):337-41.Martin T, Smith J, Rosenbaum J. Anterior uveitis: current concepts of pathogenesis and nteractions with the spondyloarthropathies. Curr Opin Rheumatol. 2002 Jul;14(4):337-41.Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004 Nov;23(6):617-37.Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004 Nov;23(6):617-37.Слепова ОС, Быковская ГН, Катаргина ТА и др. Нарушение продукции и баланса цитокинов при воспалительных заболеваниях глаз. Цитокины и воспаление. 2002;(2):59-61. [Slepova OS, Bykovskaya GN, Katargina TA, et al. The impaired production and balance of cytokines in inflammatory diseases of the eye. Tsitokiny i vospalenie. 2002;(2):59-61. (In Russ.)].Слепова ОС, Быковская ГН, Катаргина ТА и др. Нарушение продукции и баланса цитокинов при воспалительных заболеваниях глаз. Цитокины и воспаление. 2002;(2):59-61. [Slepova OS, Bykovskaya GN, Katargina TA, et al. The impaired production and balance of cytokines in inflammatory diseases of the eye. Tsitokiny i vospalenie. 2002;(2):59-61. (In Russ.)].Murphy CC, Duncan L, Forrester JV, Dick AD. Systemic CD4+ T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol. 2004 Mar;88(3):412-6.Murphy CC, Duncan L, Forrester JV, Dick AD. Systemic CD4+ T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol. 2004 Mar;88(3):412-6.El-Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011 May;139(2):177-84. doi: 10.1016/j.clim.2011.01.014. Epub 2011 Jan 31.El-Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011 May;139(2):177-84. doi: 10.1016/j.clim.2011.01.014. Epub 2011 Jan 31.Commodaro AG, Bueno V, Belfort R, Rizzo LV. Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation. Autoimmun Rev. 2011 Feb;10(4):205-9. doi: 10.1016/j.autrev.2010.10.002. Epub 2010 Oct 17.Commodaro AG, Bueno V, Belfort R, Rizzo LV. Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation. Autoimmun Rev. 2011 Feb;10(4):205-9. doi: 10.1016/j.autrev.2010.10.002. Epub 2010 Oct 17.Ермакова HA. Классификация и клиническая оценка увеитов. Клиническая офтальмология. 2003;3(4):146-9. [Ermakova NA. Classification and clinical assessment of uveitis. Klinicheskaya oftal'mologiya. 2003;3(4):146-9. (In Russ.)].Ермакова HA. Классификация и клиническая оценка увеитов. Клиническая офтальмология. 2003;3(4):146-9. [Ermakova NA. Classification and clinical assessment of uveitis. Klinicheskaya oftal'mologiya. 2003;3(4):146-9. (In Russ.)].Третьяк ЕБ, Ефремов ИН, Рябцева АА и др. Традиционные схемы терапии аутоиммунных увеитов с использованием препаратов широкого спектра действия. Клиническая офтальмология. 2002;3(5):169-72. [Tret'yak EB, Efremov IN, Ryabtseva AA, et al. Traditional therapies for autoimmune uveitis with the use of drugs of wide spectrum of action. Klinicheskaya oftal'mologiya. 2002;3(5):169-72. (In Russ.)].Третьяк ЕБ, Ефремов ИН, Рябцева АА и др. Традиционные схемы терапии аутоиммунных увеитов с использованием препаратов широкого спектра действия. Клиническая офтальмология. 2002;3(5):169-72. [Tret'yak EB, Efremov IN, Ryabtseva AA, et al. Traditional therapies for autoimmune uveitis with the use of drugs of wide spectrum of action. Klinicheskaya oftal'mologiya. 2002;3(5):169-72. (In Russ.)].Gallego-Pinazo R, Dolz-Marco R, Martinez-Castillo S, et al. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets. 2013 Feb;12(1):38-45.Gallego-Pinazo R, Dolz-Marco R, Martinez-Castillo S, et al. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets. 2013 Feb;12(1):38-45.Годзенко АА. Антицитокиновая терапия увеитов при ревматических заболеваниях. ConsiliumMedicum. 2006;8(8):10-4. [Godzenko AA. Anticytokine therapy of uveitis in rheumatic diseases. Consilium Medicum. 2006;8(8):10-4. (In Russ.)].Годзенко АА. Антицитокиновая терапия увеитов при ревматических заболеваниях. ConsiliumMedicum. 2006;8(8):10-4. [Godzenko AA. Anticytokine therapy of uveitis in rheumatic diseases. Consilium Medicum. 2006;8(8):10-4. (In Russ.)].Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014 Feb 15;8:67-81. doi: 10.2147/BTT.S41477. eCollection 2014.Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014 Feb 15;8:67-81. doi: 10.2147/BTT.S41477. eCollection 2014.Моисеенко ОМ. Эффективность дипроспана при лечении увеитов. Новое в офтальмологии. 2003;(2):32-3. [Moiseenko OM. The effectiveness of diprospan in the treatment of uveitis. Novoe v oftal'mologii. 2003;(2):32-3. (In Russ.)].Моисеенко ОМ. Эффективность дипроспана при лечении увеитов. Новое в офтальмологии. 2003;(2):32-3. [Moiseenko OM. The effectiveness of diprospan in the treatment of uveitis. Novoe v oftal'mologii. 2003;(2):32-3. (In Russ.)].Lambiase A, Abdolrahimzadeh S, Recupero SM. An update on intravitreal implants in use for eye disorders. Drugs Today (Barc). 2014 Mar;50(3):239-49. doi: 10.1358/dot.2014.50.3.2103755.Lambiase A, Abdolrahimzadeh S, Recupero SM. An update on intravitreal implants in use for eye disorders. Drugs Today (Barc). 2014 Mar;50(3):239-49. doi: 10.1358/dot.2014.50.3.2103755.Kapoor KG, Wagner MG, Wagner AL. The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease. Semin Ophthalmol. 2015 Aug 21:1-7. [Epub ahead of print].Kapoor KG, Wagner MG, Wagner AL. The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease. Semin Ophthalmol. 2015 Aug 21:1-7. [Epub ahead of print].Кацнельсон ЛА, Танковский ВЭ. Увеиты (клиника, лечение). Москва: 4-й филиал Воениздата; 2003. 286 с. [Katsnel'son LA, Tankovskii VE. Uveity (klinika, lechenie) [Uveitis (clinic, treatment)]. Moskva: 4-i filial Voenizdata; 2003. 286 p.]Кацнельсон ЛА, Танковский ВЭ. Увеиты (клиника, лечение). Москва: 4-й филиал Воениздата; 2003. 286 с. [Katsnel'son LA, Tankovskii VE. Uveity (klinika, lechenie) [Uveitis (clinic, treatment)]. Moskva: 4-i filial Voenizdata; 2003. 286 p.]Islam N1, Pavesio C. Uveitis (acute anterior). BMJ Clin Evid. 2010 Apr 8;2010. pii: 0705.Islam N1, Pavesio C. Uveitis (acute anterior). BMJ Clin Evid. 2010 Apr 8;2010. pii: 0705.Foster CS. Vitale AT, editors. Diagnosis and treatment of uveitis. Philadelphia: W.B. Saunders Company; 2002. 900 p.Foster CS. Vitale AT, editors. Diagnosis and treatment of uveitis. Philadelphia: W.B. Saunders Company; 2002. 900 p.Androudi S, Brazitikos P, Iaccheri B, et al. Outcomes of early and late immunomodulatory treatment in patients with HLA-B27-associated chronic uveitis. Graefes Arch Clin Exp Ophthalmol. 2003 Dec;241(12):1000-5. Epub 2003 Nov 7.Androudi S, Brazitikos P, Iaccheri B, et al. Outcomes of early and late immunomodulatory treatment in patients with HLA-B27-associated chronic uveitis. Graefes Arch Clin Exp Ophthalmol. 2003 Dec;241(12):1000-5. Epub 2003 Nov 7.Катаргина ЛА, Архипова ЛТ. Увеиты: патогенетическая иммуносупрессивная терапия. Тверь: Триада; 2004. 77 с. [Katargina LA, Arkhipova LT. Uveity: patogeneticheskaya immunosupressivnaya terapiya [Uveitis: pathogenic and immunosuppressive therapy]. Tver': Triada; 2004. 77 p.]Катаргина ЛА, Архипова ЛТ. Увеиты: патогенетическая иммуносупрессивная терапия. Тверь: Триада; 2004. 77 с. [Katargina LA, Arkhipova LT. Uveity: patogeneticheskaya immunosupressivnaya terapiya [Uveitis: pathogenic and immunosuppressive therapy]. Tver': Triada; 2004. 77 p.]Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010 Mar;117(3):576-84. doi: 10.1016/j.ophtha.2009.08.010. Epub 2010 Jan 19.Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010 Mar;117(3):576-84. doi: 10.1016/j.ophtha.2009.08.010. Epub 2010 Jan 19.Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009 Nov;116(11):2188-98.e1. doi: 10.1016/j.ophtha.2009.04.020. Epub 2009 Sep 12.Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009 Nov;116(11):2188-98.e1. doi: 10.1016/j.ophtha.2009.04.020. Epub 2009 Sep 12.Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009 Oct;148(4):500-509.e2. doi: 10.1016/j.ajo.2009.05.008. Epub 2009 Jul 1.Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009 Oct;148(4):500-509.e2. doi: 10.1016/j.ajo.2009.05.008. Epub 2009 Jul 1.Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010 Feb;117(2): 356-65. doi: 10.1016/j.ophtha.2009.06.060. Epub 2009 Dec 6.Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010 Feb;117(2): 356-65. doi: 10.1016/j.ophtha.2009.06.060. Epub 2009 Dec 6.Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001 Jun;108(6):1134-9.Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001 Jun;108(6):1134-9.Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003 Jun;30(6):1277-9. 78. Kruithof E, Kestelyn P, Elewaut C, et al. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann Rheum Dis. 2002 May;61(5):470.Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003 Jun;30(6):1277-9. 78. Kruithof E, Kestelyn P, Elewaut C, et al. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann Rheum Dis. 2002 May;61(5):470.Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford). 2009 Sep;48(9):1029-35. doi: 10.1093/rheumatology/kep146. Epub 2009 Jun 26.Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford). 2009 Sep;48(9):1029-35. doi: 10.1093/rheumatology/kep146. Epub 2009 Jun 26.Braun J, Baraliakos X, Listing J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005 Aug;52(8):2447-51.Braun J, Baraliakos X, Listing J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005 Aug;52(8):2447-51.Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondyloarthropathy: a retrospective study. Ann Rheum Dis. 2006 Dec;65(12):1631-4. Epub 2006 Aug 10.Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondyloarthropathy: a retrospective study. Ann Rheum Dis. 2006 Dec;65(12):1631-4. Epub 2006 Aug 10.Rudwaleit M, Rњdevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009 May;68(5):696-701. doi: 10.1136/ard.2008. 092585. Epub 2008 Jul 28.Rudwaleit M, Rњdevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009 May;68(5):696-701. doi: 10.1136/ard.2008. 092585. Epub 2008 Jul 28.Hale S, Lightman S. Anti-TNF therapies in management of acute and chronic uveitis. Cytokine. 2006 Feb 21;33(4):231-7. Epub 2006 Mar 15.Hale S, Lightman S. Anti-TNF therapies in management of acute and chronic uveitis. Cytokine. 2006 Feb 21;33(4):231-7. Epub 2006 Mar 15.Levy-Clarke G, Jabs DA, Read RW, et al. Expert Panel Recommendations for the Use of AntieTumor Necrosis Factor Biologic Agents in Patients with Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17.Levy-Clarke G, Jabs DA, Read RW, et al. Expert Panel Recommendations for the Use of AntieTumor Necrosis Factor Biologic Agents in Patients with Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17.El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. 2002 Dec;109(12):2342-6.El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. 2002 Dec;109(12):2342-6.Сигидин ЯА, Лукина ГВ. Биологическая терапия в ревматологии. Москва: Практическая Медицина; 2009. 302 с. [Sigidin YaA, Lukina GV. Biologicheskaya terapiya v revmatologii [Biological therapy in rheumatology]. Moscow: Prakticheskaya Meditsina; 2009. 302 p.]Сигидин ЯА, Лукина ГВ. Биологическая терапия в ревматологии. Москва: Практическая Медицина; 2009. 302 с. [Sigidin YaA, Lukina GV. Biologicheskaya terapiya v revmatologii [Biological therapy in rheumatology]. Moscow: Prakticheskaya Meditsina; 2009. 302 p.]Suhler EB, Smith JR, Wertheim MS. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005 Jul;123(7):903-12.Suhler EB, Smith JR, Wertheim MS. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005 Jul;123(7):903-12.Taban M, Dupps WJ, Mandell B. Etanercept-associated inflammatory eye diseas: case report and review of the literature. Ocul Immunol Inflamm. 2006 Jun;14(3):145-50.Taban M, Dupps WJ, Mandell B. Etanercept-associated inflammatory eye diseas: case report and review of the literature. Ocul Immunol Inflamm. 2006 Jun;14(3):145-50.Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011 Dec;41(3):503-10. doi: 10.1016/j.semarthrit.2011.05.005. Epub 2011 Aug 20.Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011 Dec;41(3):503-10. doi: 10.1016/j.semarthrit.2011.05.005. Epub 2011 Aug 20.Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013 Mar-Apr;31(2):320-1. Epub 2013 Jan 18.Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013 Mar-Apr;31(2):320-1. Epub 2013 Jan 18.Wendling D, Dernis E, Prati C, et al. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? J Rheumatol. 2011 Oct;38(10):2284. doi: 10.3899/jrheum.110170.Wendling D, Dernis E, Prati C, et al. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? J Rheumatol. 2011 Oct;38(10):2284. doi: 10.3899/jrheum.110170.Esterberg E, Acharya NR. Corticosteroidsparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect. 2012 Mar;2(1):21-8. doi: 10.1007/s12348-011-0047-5. Epub 2011 Nov 6.Esterberg E, Acharya NR. Corticosteroidsparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect. 2012 Mar;2(1):21-8. doi: 10.1007/s12348-011-0047-5. Epub 2011 Nov 6.

The authors declare that there are no conflicts of interest present.